Pharmaceutical agents
AssigneeImperial Chemical Industries PLC
InventorMurray W. Cuthbert
Life of this patent
Estimating the term…
Abstract
A physical form of (R)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol -3-ylmethyl]-N-(2-methylphenylsulphonyl)benzamide substantially free of other physical forms, which form is crystalline and has an X-ray powder diffraction pattern with specific peaks at 2.theta.=14.0, 19.4, 22.0, 22.4 and 24.7.degree. , processes for preparing the form and pharmaceutical compositions containing it. The compound is a leukotriene antagonist useful in the treatment of diseases such as asthma.
Claims6
A physical form of (R)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol- 3-ylmethyl]-N-(2-methylphenylsulphonyl)benzamide, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks at 2.theta.=14.0, 19.4, 22.0, 22.4 and 24.7.degree., has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3390, 1620, 1250 and 885 cm.sup.-1, and has a melting point of 180.degree.-183 .degree. C.
A physical form of (R)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol- 3-ylmethyl]-N-(2-methylphenylsulphonyl)benzamide, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks at 2.theta.=14.0, 19.4, 22.0, 22.4 and 24.7.degree., has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3390, 1620, 1250 and 885 cm.sup.-1, and has an endotherm maximum determined by differential scanning calorimetry (heating rate 10.degree. C./minute) of above 180 .degree. C.
A pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a physical form of (R)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol- 3-ylmethyl]-N-(2-methylphenylsulphonyl)benzamide, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks at 2.theta.=14.0, 19.4, 22.0, 22.4 and 24.7.degree., has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3390, 1620, 1250 and 885 cm.sup.-1, and has a melting point of 180.degree.-183 .degree. C.
A pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a physical form of (R)-3-methoxy-4-[1-methyl-5-(2-methyl-4,4,4-trifluorobutylcarbamoyl)indol- 3-ylmethyl]-N-(2-methylphenylsulphonyl)benzamide, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks at 2.theta.=14.0, 19.4, 22.0, 22.4 and 24.7.degree., has an infra-red spectrum (0.5% in KBr) having sharp peaks at 3390, 1620, 1250 and 885 cm.sup.-1, and has an endotherm maximum determined by differential scanning calorimetry (heating rate 10 .degree. C./minute) of above 180 .degree. C.
Dependencies are inferred from the claim text.